Background: Chromic inflammation is involved in dysfunction and loss of neurons in neurodegenerative diseases. The comple- ment system is required for activation of microglia, which might induce phagocytosis of Abeta and also neurons in the brain. Activation of the classical complement pathway and the resident microglia in the brain may be related to synapse failure and loss of neurons in pathogenesis of Alzheimer’s dis- ease (AD). We reported the clinical potential of complement C3 (C3), apolipoprotein A1 (apoA1), and transthyretin (TTR) in the assessment of cognitive decline by longitudinal and cross-sectional cohort studies (Alzheimer Dement (Amst) 1: 270-280, 2015). In this study, we measured peripheral levels of both inactivated and activated complement proteins in mild cognitive impairment (MCI), AD, and non-demented healthy control (NDC). Methods: The complement protein is proteolytically cleaved during its activation. We developed immunoassay which differentially detected an inactive (inC3) and active (aC3) forms of C3. Peripheral profiles of them were analyzed immunoassay using specific antibodies raised against each form of C3. We also analyzed complement- derived peptides of C3 and C4 in both serum and the brain by LC-MS/MS to assess their clinical potential for evaluation of cognitive impairment. The least absolute shrinkage and se- lection operator was used to evaluate the combination of mul- tiple biomarkers. Results: A combination of inC3, apoA1, and TTR achieved an area under the curve (AUC) of 0.85 (sensi- tivity: 75% and specificity: 90%) in MCI vs. NDC, and the combination of aC3/inC3 ratio, apoA1, and TTR improved value of AUC to 0.87 (sensitivity: 90% and specificity: 83%). By LC-MS/MS, we found novel peptide fragments of comple- ment proteins showing clinical potential in diagnosis of MCI and AD. Immunohistochemistry and LC-MS/MS anlyses of serum and the brain tissues, including the hippocampus, frontal lobe, and cerebellum, from definite AD and NDC revealed that levels of fragments of C3 and C4 including novel peptides were significantly elevated in both serum and the brain from AD comparing to NDC subjects. Conclusions: The current study in- dicates that peripheral profiles of activated fragments and inac- tivated form of complement proteins are related to cognitive decline in MCI and AD. P2-265 GLYCEMIC VARIABILITY IN ACUTE ISCHEMIC STROKE AND COGNITIVE OUTCOME Jae-Sung Lim 1 , Chulho Kim 2 , Mi Sun Oh 1 , Sang Won Suh 3 , Byung-Chul Lee 1 , Kyung-Ho Yu 1 , 1 Hallym University Sacred Heart Hospital, Anyang, Republic of South Korea; 2 Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of South Korea; 3 Hallym University, College of Medicine, Chuncheon, Republic of South Korea. Contact e-mail: rophe.pneuma@gmail.com Background: Post-stroke cognitive impairment (PSCI) is one of the major burdens for stroke survivors. Poorly controlled hy- perglycemia and hypoglycemic events are well-known predic- tors for cognitive impairment. We aimed to investigate the effect of glycemic variability in the acute stroke on the devel- opment of PSCI. Methods: Patients hospitalized with acute ischemic stroke in a university hospital were enrolled. Blood glucose levels were queried using clinical database warehouse in electronic medical records, and patients with at least 5 times blood glucose levels within 7 days after stroke onset were included. Glycemic variability variables – standard deviation (SD), coefficients of variances (CVs% ¼ SD/mean * 100), mean absolute glucose (MAG, P jDGlucosej/ P DTime) – were calculated. Detailed neuropsychological assessments were administered at 3 to 6 months after stroke. Primary outcome was the occurrence of PSCI, which was defined as a score of less than -2 SD for age-, sex-, and education-adjusted mean in at least one cognitive domain. Odds ratios were calcu- lated using multiple logistic regression analysis. Results: A total of 361 patients were enrolled. (mean age 63.1612.0, median score of initial National Institutes of Health Stroke Scale 2, me- dian number of blood glucose evaluations 14). Diabetes melli- tus was observed in 88 (24.4%) patients. PSCI was developed in 80 (22.2%) patients, and those with PSCI were significant older, and more likely to be female, and had more severe stroke compared to those without PSCI. There were no significant dif- ferences in the proportion of patients with diabetes mellitus or in mean values of HbA1c according to 3-month cognitive outcome. In diabetic group, SD and MAG have been identified as significant predictors for PSCI (adjusted OR for SD 1.81, 95% CI 1.04-3.16; adjusted OR for MAG 1.94, 95% CI 1.14- 3.29). Meanwhile, SD and MAG showed martial significances in non-diabetic group, though the PSCI had an increasing ten- dency along the higher tertiles of SD and MAG. Conclusions: Glycemic variability during acute ischemic stroke was identi- fied as novel predictor for PSCI. As the modifiable risk factor for PSCI, glycemic variability might be considered as an important monitoring parameter and treatment target in acute stroke. P2-266 APATHY IMPAIRS ADVANCED ACTIVITIES OF DAILY LIVING IN VERY MILD ALZHEIMER DISEASE Carolina Delgado 1 , Rodrigo Vergara 2 , Melissa Martinez, Sr, 1 , Gada Musa 2 , Fernando Henriquez 1 , Andrea Slachevsky 3,4,5,6,7 , 1 Universidad de Chile, Santiago, Chile; 2 Universidad de Chile, Santiago, Chile; 3 Physiopathology Department, ICBM y East Neuroscience Department, Faculty of Medicine, University of Chile, Providencia,, Santiago, Chile; 4 Centre for Advanced Research in Education, Santiago, Chile; 5 Servicio de Neurolog ıa, Departamento de Medicina, Cl  ınica Alemana-Universidad del Desarrollo, Santiago, Chile; 6 Cognitive Neurology and Dementia, Neurology Department, Hospital del Salvador, Santiago, Chile; 7 Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile. Contact e-mail: carodede@gmail.com Background: Although Alzheimer disease (AD) is clinically defined by progressive memory decline, neuropsychiatric symptoms (NPS) are present from very early stages, being apathy the most common NPS. Disease evolution is character- ized by progressive impairment in activities of daily living (ADL) from very mild impairment in mild cognitive impair- ment (MCI) to total dependency in the severe states. In addi- tion, ADL could be divided in basic (selfcare), instrumental (household, shopping, travel, communication), and advances ones (work, use of technology) being the last the first affected in symptomatic AD. Objectives: 1. Analyze the factors related with ADL impairment in at different stages of AD: very mild o MCI, and mild to moderate AD. 2. Analyse the factors related with different types of ADL: basic, instrumental and advanced. Poster Presentations: Monday, July 17, 2017 P715